Compare · ARVN vs GLUE

ARVN vs GLUE

Side-by-side comparison of Arvinas Inc. (ARVN) and Monte Rosa Therapeutics Inc. (GLUE): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. ARVN focuses on Biotechnology: Pharmaceutical Preparations, while GLUE focuses on Biotechnology: Biological Products (No Diagnostic Substances).
  • GLUE is the larger of the two at $738.3M, about 1.7x ARVN ($423.0M).
  • GLUE has been more active in the news (10 items in the past 4 weeks vs 9 for ARVN).
  • ARVN has more recent analyst coverage (25 ratings vs 12 for GLUE).
MetricARVNGLUE
Company
Arvinas Inc.
Monte Rosa Therapeutics Inc.
Price
-
-
Market cap
$423.0M
$738.3M
1M return
-
-22.16%
1Y return
-
-45.20%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NASDAQ
IPO
2018
2021
News (4w)
9
10
Recent ratings
25
12
ARVN

Arvinas Inc.

Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Bayer AG, and Insilico Medicine, Inc. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.

Latest ARVN

Latest GLUE